Compare Medpace Holdings Inc (MEDP) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Orion Office REIT Inc — how do they compare? Medpace Holdings Inc trades at $615.82 (market cap $16.82B), while Orion Office REIT Inc trades at $2.21 (market cap $125.50M). The key difference: Medpace Holdings Inc is far larger — about 134× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Orion Office REIT Inc for 33 Days on average.
| MEDP | ONL | |
|---|---|---|
Market Cap | $16.82B | $125.50M |
Volume | 223,093 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $630.19 | $3.00 |
52-Week Low | $393.42 | $1.93 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | $16.44B | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
ONL trades at $2.20, down 3.08% with a bearish technical signal despite oscillators showing some bullish momentum. The company shows declining revenue from $208M in 2022 to $148M in 2025 with persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics show low P/S (0.88) and P/B (0.2) ratios, while analyst sentiment is split evenly between Buy and Hold recommendations.
The outlook remains challenging with ongoing revenue declines and negative profitability, though deep valuation discounts and strategic portfolio repositioning offer potential upside. Key risks include high debt levels, office sector headwinds, and execution challenges in turning around financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
